Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Feb 14, 2005; 11(6): 771-777
Published online Feb 14, 2005. doi: 10.3748/wjg.v11.i6.771
Published online Feb 14, 2005. doi: 10.3748/wjg.v11.i6.771
Table 3 Inhibitory effect of fumagillin on hepatic tumor growth and metastasis in LEW rats at wk 20 and 24.
Treatment groups | Liver tumor (B/C-A) (g, median) | No. of HCC-involved organs1 | ||
20th wk | 24th wk | 20th wk | 24th wk | |
Group B DEN only (n = 5) | 0.641 | 0.791 | 3 | 3 |
[0.58-0.70] | [0.70-0.90] | [2-3] | [3-3] | |
Group C DEN + Fumagillin (n = 5) | 0.37 | 0.39 | 1 | 1 |
[0.35-0.42] | [0.35-0.47] | [1-2] | [1-2] | |
P value | 0.009 | 0.009 | 0.007 | 0.004 |
-
Citation: Sheen IS, Jeng KS, Jeng WJ, Jeng CJ, Wang YC, Gu SL, Tseng SY, Chu CM, Lin CH, Chang KM. Fumagillin treatment of hepatocellular carcinoma in rats: An
in vivo study of antiangiogenesis. World J Gastroenterol 2005; 11(6): 771-777 - URL: https://www.wjgnet.com/1007-9327/full/v11/i6/771.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i6.771